Overview

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Status:
Completed
Trial end date:
2009-01-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and activity of MNTX in relieving opioid-induced constipation following orthopedic procedures.
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Bromides
Methylnaltrexone
Naltrexone